Localized bone disease as a presentation of hairy cell leukemia

Clinical Advances in Hematology and Oncology

Volumn 6, Issue 4, 2008, Pages 290-294

  Karmali, Reem ^a   Farhat, Mohamed ^a   Leslie, William ^a   McIntire, Maria G ^a   Gregory, Stephanie ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE;

ADULT; ALBRIGHT SYNDROME; ANAMNESIS; ARTICLE; BONE BIOPSY; BONE DISEASE; BONE MARROW BIOPSY; BONE SCINTISCANNING; CASE REPORT; FLOW CYTOMETRY; FOLLOW UP; HAIRY CELL LEUKEMIA; HIP PAIN; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOPROLIFERATIVE DISEASE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; BONE MARROW EXAMINATION; FEMUR HEAD; PATHOLOGY;

ADULT; BONE DISEASES; BONE MARROW EXAMINATION; FEMUR HEAD; HUMANS; LEUKEMIA, HAIRY CELL; MALE; POSITRON-EMISSION TOMOGRAPHY;

EID: 46449128282     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Lal A, Tallman MS, Soble MB, et al. Hairy cell leukemia presenting as localized skeletal involvement. Leuk Lymphoma. 2002;43:2207-2211. (Pubitemid 35174735)
2. Tiacci E, Liso A, Piris M, Falini B. Evolving concepts in the pathogenesis of hairy-cell leukaemia. Nat Rev Cancer. 2006; 6:437-448.
3. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. 1958;13:609-629.
4. Schrek R, Donnelly WJ. "Hairy" cells in blood in lymphoreticular neoplastic disease and "flagellated" cells of normal lymph nodes. Blood. 1966;27:199-211.
5. Basso K, Liso A, Tiacci E, et al. Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med. 2004;199:59-68. (Pubitemid 38076478)
6. Falini, B, Tiacci, E, Liso, A, et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet. 2004;363:1869-1870. (Pubitemid 38748643)
7. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265-276.
8. Quesada JR, Keating MJ, Libshitz HI, Llamas L. Bone involvement in hairy cell leukemia. Am J Med. 1983;74:228-231. (Pubitemid 13192178)
9. VanderMolen LA, Urba WJ, Longo DL, Lawrence J, Gralnick H, Steis RG. Diffuse osteosclerosis in hairy cell leukemia. Blood. 1989;74:2066-2069. (Pubitemid 19269111)
10. Herold CJ, Wittich GR, Schwarzinger I, et al. Skeletal involvement in hairy cell leukemia. Skeletal Radiol. 1988;17:171-175. (Pubitemid 18106823)
11. Lembersky BC, Ratain MJ, Golomb HM. Skeletal complications in hairy cell leukemia: diagnosis and therapy. J Clin Oncol. 1988;6:1280-1284. (Pubitemid 18196806)
12. Schirrmeister H, Guhlmann A, Kotzerke J, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol. 1999;17:2381-2389. (Pubitemid 29368236)
13. Schirrmeister H, Glatting G, Hetzel J, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001;42:1800-1804. (Pubitemid 34016348)
14. Kato H, Miyazaki T, Nakajima M, et al. Comparison between whole-body positron emission tomography and bone scintigraphy in evaluating bony metastases of esophageal carcinomas. Anticancer Res. 2005;25:4439-4444. (Pubitemid 41729493)
15. Seemann MD, Meisetschlaeger G, Gaa J, Rummeny EJ. Assessment of the extent of metastases of gastrointestinal carcinoid tumors using whole-body PET, CT, MRI, PET/CT and PET/MRI. Eur J Med Res. 2006; 11:58-65. (Pubitemid 43336943)
16. Park YH, Kim S, Choi SJ, et al. Clinical impact of whole-body FDG-PET for evaluation of response and therapeutic decision-making of primary lymphoma of bone. Abstract published in the Abstract Book of the 29th ESMO Congress, Vienna, Austria; Oct 29-Nov 2, 2004.
17. Tallman MS, Hakimian D. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood. 1995;86:2463-2474
18. Saven A, Cheung, WK Smith I, et al. Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. J Clin Oncol. 1996;14:978-983. (Pubitemid 126425572)
19. Zinzani PL, Tani M, Marchi E, et al. Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica. 2004;89:309-313. (Pubitemid 38788415)
20. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med. 1990;322:1117-1121. (Pubitemid 20149529)
21. Saven A, Burian C, Koziol JA, et al. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood. 1998;92:1918-1926. (Pubitemid 28446680)
22. Else M, Ruchlemer R, Osuji N, et al. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer. 2005;104:2442-2448. (Pubitemid 41691566)
23. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood. 2001;97:101-106. (Pubitemid 32061248)
24. Thomas DA, O'Brien S, Bueso-Ramos C, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood. 2003;102(12):3906-3911. (Pubitemid 37486969)
25. Ravandi F, Jorgensen JL, O'Brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood. 2006;107:4658-4662. (Pubitemid 43882611)